SCHEMBL5647604

SCHEMBL5647604

CCN(CC)CCCNC(=O)c1ccc(-c2nc3ncccc3[nH]2)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
TP53 P04637 3/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GLA P06280 1/20 0.43
PDE5A O76074 6/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
PRMT5 O14744 1/20 0.41
WDR77 Q9BQA1 1/20 0.41
PDE4A P27815 2/20 0.40
PDE4B Q07343 2/20 0.40
PDE4C Q08493 2/20 0.40
PDE4D Q08499 2/20 0.40
KMT2A Q03164 1/20 0.40
CAMK2D Q13557 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654376 0.90 TSHR (0.43) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5651088 0.89 PDE2A (0.52) TSHRKDM4EHSD17B10HTTPDE5A
SCHEMBL5650407 0.87 APLNR (0.47) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5651923 0.85 PRKD3 (0.45) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5653615 0.83 HDAC6 (0.46) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5649255 0.81 PRSS12 (0.50) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5647370 0.80 POLB (0.51) TSHRKDM4EHSD17B10HTTSMN1; SMN2
SCHEMBL5651662 0.80 HTT (0.49) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5651653 0.80 HTT (0.49) TSHRTP53GAAKDM4EHSD17B10
SCHEMBL5650419 0.80 TP53 (0.46) TSHRTP53GAAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 TSHR 161/4885TP53 4051/4885GAA 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.